Burosumab Biosimilar Monoclonal Antibody (FGF23) for Research
Pre-Made Burosumab biosimilar, Whole mAb, Anti-FGF23 Antibody: Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Burosumab (INN, sold under the brand name Crysvita) is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.[ Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018.[8] The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was approved for use in the European Union in February 2018.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-086-1mg | 1mg | 243 |
Size: 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Burosumab biosimilar, Whole mAb, Anti-FGF23 Antibody: Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC therapeutic antibody |
| INN Name | Burosumab |
| Target | FGF23 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Kyowa Hakko Kirin;Ultragenyx Pharmaceutical |
| Conditions Approved | X-linked dominant hypophosphataemic rickets;Osteomalacia |
| Conditions Active | Nevus |
| Conditions Discontinued | na |
| Development Tech | na |
About target - FGF23
1. Protein Fibroblast growth factor 23
2. Gene FGF23
3. Organism Homo sapiens (Human)
Function
Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL (By similarity).
Acts directly on the parathyroid to decrease PTH secretion (By similarity).
Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.

